ASCO chose Micromedic's CD24 project as one of 4 leading studies for 2009

Jan. 27, 2010 - PRLog -- Micromedic Technologies LTD, the sponsor of Prof. Arber's study demonstrating CD24 as a biomarker for colorectal cancer, is proud to report that the American Society of Clinical Oncology (ASCO) has selected the study as one of four most important and promising studies for 2009. In their statement ASCO said "Simple blood test detects colorectal cancer and colorectal adenomas: A new test for blood levels of the CD24 protein is more than 90 percent sensitive and specific for detecting colorectal cancer, and more than 80 percent accurate at detecting potential pre-cancers, called adenomas. These findings may prove useful for identifying patients who would benefit most from colonoscopy"
(http://www.asco.org/ASCOv2/Press+Center/Latest+News+Releases/Meetings+News/Studies+Advance+Detection+and+Treatment+of+Gastrointestinal+Cancers)
Micromedic Technologies LTD, via its subsidiary Bio-Mark LTD, has been sponsoring Prof. Arber's study in the last few years. The company is translating the study into a valid and usable in vitro diagnostics tool/test for colorectal adenoma detection – aiming to point those at risk to develop colorectal cancer to treatment at the earliest – and thus curable – stage.  Please log on to http://www.m-medic.com/biomark.html for more information.

# # #

Micromedic, publicly traded company listed on Tel Aviv Stock Exchange. The Company's main business is licensing, translating and commercializing new promising early-detection and monitoring biomarkers for various autoimmune clinical conditions.